These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
208 related articles for article (PubMed ID: 24576297)
21. YKL-40 in induced sputum after allergen bronchial provocation in atopic asthma. Lee JH; Park KH; Park JW; Hong CS J Investig Allergol Clin Immunol; 2012; 22(7):501-7. PubMed ID: 23397672 [TBL] [Abstract][Full Text] [Related]
22. Early pulmonary inflammation in infants with cystic fibrosis. Khan TZ; Wagener JS; Bost T; Martinez J; Accurso FJ; Riches DW Am J Respir Crit Care Med; 1995 Apr; 151(4):1075-82. PubMed ID: 7697234 [TBL] [Abstract][Full Text] [Related]
23. Identification of neutrophil activation markers as novel surrogate markers of CF lung disease. Rath T; Zwaschka L; Hage L; Kügler M; Menendez K; Naehrlich L; Schulz R; Roderfeld M; Roeb E PLoS One; 2014; 9(12):e115847. PubMed ID: 25545245 [TBL] [Abstract][Full Text] [Related]
24. Distinct patterns of inflammation in the airway lumen and bronchial mucosa of children with cystic fibrosis. Regamey N; Tsartsali L; Hilliard TN; Fuchs O; Tan HL; Zhu J; Qiu YS; Alton EW; Jeffery PK; Bush A; Davies JC Thorax; 2012 Feb; 67(2):164-70. PubMed ID: 22008188 [TBL] [Abstract][Full Text] [Related]
25. Fractional analysis of bronchoalveolar lavage fluid cytology in cystic fibrosis patients with normal lung function. Bronchoalveolar lavage for the evaluation of anti-inflammatory treatment (BEAT) study group. Ratjen F; Rietschel E; Griese M; Ballmann M; Kleinau I; Döring G; Reinhardt D; Paul K Eur Respir J; 2000 Jan; 15(1):141-5. PubMed ID: 10678636 [TBL] [Abstract][Full Text] [Related]
26. YKL-40 as marker of severe lung disease in cystic fibrosis patients. Leonardi S; Parisi GF; Capizzi A; Manti S; Cuppari C; Scuderi MG; Rotolo N; Lanzafame A; Musumeci M; Salpietro C J Cyst Fibros; 2016 Sep; 15(5):583-6. PubMed ID: 26778616 [TBL] [Abstract][Full Text] [Related]
27. YKL-40 is elevated in patients with chronic obstructive pulmonary disease and activates alveolar macrophages. Létuvé S; Kozhich A; Arouche N; Grandsaigne M; Reed J; Dombret MC; Kiener PA; Aubier M; Coyle AJ; Pretolani M J Immunol; 2008 Oct; 181(7):5167-73. PubMed ID: 18802121 [TBL] [Abstract][Full Text] [Related]
36. Risk factors for bronchiectasis in children with cystic fibrosis. Sly PD; Gangell CL; Chen L; Ware RS; Ranganathan S; Mott LS; Murray CP; Stick SM; N Engl J Med; 2013 May; 368(21):1963-70. PubMed ID: 23692169 [TBL] [Abstract][Full Text] [Related]
37. Elevated circulating levels of the serum acute-phase protein YKL-40 (chitinase 3-like protein 1) are a marker of obesity and insulin resistance in prepubertal children. Kyrgios I; Galli-Tsinopoulou A; Stylianou C; Papakonstantinou E; Arvanitidou M; Haidich AB Metabolism; 2012 Apr; 61(4):562-8. PubMed ID: 22036069 [TBL] [Abstract][Full Text] [Related]
38. Association of Antibiotics, Airway Microbiome, and Inflammation in Infants with Cystic Fibrosis. Pittman JE; Wylie KM; Akers K; Storch GA; Hatch J; Quante J; Frayman KB; Clarke N; Davis M; Stick SM; Hall GL; Montgomery G; Ranganathan S; Davis SD; Ferkol TW; Ann Am Thorac Soc; 2017 Oct; 14(10):1548-1555. PubMed ID: 28708417 [TBL] [Abstract][Full Text] [Related]
39. Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4 ratio in children with cystic fibrosis. Ringholz FC; Buchanan PJ; Clarke DT; Millar RG; McDermott M; Linnane B; Harvey BJ; McNally P; Urbach V Eur Respir J; 2014 Aug; 44(2):394-404. PubMed ID: 24696116 [TBL] [Abstract][Full Text] [Related]
40. Human neutrophil elastase and elastase/alpha 1-antiprotease complex in cystic fibrosis. Comparison with interstitial lung disease and evaluation of the effect of intravenously administered antibiotic therapy. Meyer KC; Lewandoski JR; Zimmerman JJ; Nunley D; Calhoun WJ; Dopico GA Am Rev Respir Dis; 1991 Sep; 144(3 Pt 1):580-5. PubMed ID: 1892298 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]